Cafepharma Today

June 3 2025 - Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech
Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech
Arrowhead commences dosing in Phase I/IIa obesity treatment trial
ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop
Amid staff cuts, FDA looks to AI to 'optimize' reviews
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Sepracor says it's staying put
Fierce Biotech
Saturday, September 5, 2009 - 12:43pm
tags:
Sepracor, M&A
Biogen Idec offers to buy Facet for $356M
Bizjournals.com
Saturday, September 5, 2009 - 12:41pm
tags:
Biogen Idec, Facet Biotech, M&A
King and Acura say FDA may not need more tests of abuse-resisting pain drug during review
Yahoo/AP
Saturday, September 5, 2009 - 12:39pm
tags:
King, FDA, Acura Pharmaceuticals, painkillers, Acurox
Big fines unlikely to steer drug companies from marketing drugs for unapproved uses
Yahoo/AP
Saturday, September 5, 2009 - 12:37pm
tags:
off-label, Pfizer, Bextra
FDA: Merck's vaccine for cervical cancer also prevents most cases of genital warts in males
Yahoo/AP
Saturday, September 5, 2009 - 12:11pm
tags:
Merck, genital wars, FDA, HPV, Gardasil
Spectrum's Zevalin OK'd for New Use
TheStreet.com
Saturday, September 5, 2009 - 12:07pm
tags:
Spectrum Pharmaceuticals, Zevalin, non-Hodgkin's lymphoma, FDA
FDA Reviewing Bristol Transplant Drug
Yahoo/AP
Friday, September 4, 2009 - 9:52am
tags:
FDA, transplant drugs, Bristol-Myers Squibb, belatacept, AstraZeneca, Eli Lilly
Hot Biotech Events for Next Week: BioBuzz
TheStreet.com
Friday, September 4, 2009 - 8:48am
tags:
biotech, Elan, Geron, Cell Therapeutics, Genta, Antigenics, Vivus, Osiris Therapeutics
Study: New, unlicensed swine flu treatment could help patients with Tamiflu-resistant viruses
Yahoo/AP
Friday, September 4, 2009 - 8:46am
tags:
Tamiflu, swine flu, H1N1, RELENZA, GSK
FDA To Review Takeda’s sNDA For Velcade
Pharmaceutical Business Review
Friday, September 4, 2009 - 7:47am
tags:
Takeda, sNDA, Velcade, FDA, Multiple Myeloma
Adeona Prepares Three Drugs for NDA Submission
Offical Wire
Friday, September 4, 2009 - 7:44am
tags:
NDA, FDA, Adeona, Trimesta, MS, Zinthionein, macular degeneration, JP1, rheumatoid arthritis
Gilead Sciences: Expect Share Price to Move Up
Seeking Alpha
Friday, September 4, 2009 - 7:42am
tags:
Gilead Sciences, antivirals
Weighing Arena's Obesity Drug: Biotech Mailbag
TheStreet.com
Friday, September 4, 2009 - 7:41am
tags:
Arena Pharmaceuticals, obesity, Biovest International, Vivus, Orexigen, Qnexa, lorcaserin
Market Curveball: Swine Flu
CNBC
Friday, September 4, 2009 - 7:40am
tags:
Sinovac, China, H1N1, vaccines, swine flu
Allos Therapeutics: Prospects for FDA Approval of Folotyn Are Healthy
Seeking Alpha
Friday, September 4, 2009 - 7:11am
tags:
Allos, Folotyn, FDA
Bayer's Bold New Bet Fails to Rain on Spectrum Pharma
Seeking Alpha
Friday, September 4, 2009 - 6:21am
tags:
Bayer, Spectrum Pharmaceuticals
Abbott: Now That's How to Grow a Company!
Motley Fool
Friday, September 4, 2009 - 6:19am
tags:
Abbott Laboratories, Merck, Schering Plough, Visiogen, M&A
Elan dealt a blow with Biogen ruling
FT.com
Thursday, September 3, 2009 - 10:00pm
tags:
Elan, Biogen Idec, JNJ
Merck: 3 Schering-Plough directors to join board
Yahoo/AP
Thursday, September 3, 2009 - 9:59pm
tags:
Merck, buyouts, reorganization, Schering Plough
Shire wins U.S. approval for Intuniv drug
Reuters
Thursday, September 3, 2009 - 5:23pm
tags:
Shire, Intuniv, FDA, ADHD

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.